{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T15:57:43Z","timestamp":1760889463019,"version":"build-2065373602"},"reference-count":35,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,2,1]],"date-time":"2018-02-01T00:00:00Z","timestamp":1517443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1016\/j.bmc.2017.09.008","type":"journal-article","created":{"date-parts":[[2017,9,7]],"date-time":"2017-09-07T21:31:42Z","timestamp":1504819902000},"page":"957-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency"],"prefix":"10.1016","volume":"26","author":[{"given":"Jiping","family":"Fu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher","family":"Becker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Capparelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regis","family":"Denay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"Fujimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Gai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaobo","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Guenat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Subramanian","family":"Karur","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongyong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weikuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lochmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amy","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peichao","family":"Lu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Luneau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Meier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wosenu","family":"Mergo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Ng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Parker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yunshan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernard","family":"Riss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexey","family":"Rivkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silvio","family":"Roggo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harald","family":"Schroeder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Friedrich","family":"Schuerch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert L.","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zachary K.","family":"Sweeney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meiliana","family":"Tjandra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ruidong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew H.","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Wenger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quanbing","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Su","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenjian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aregahegn","family":"Yifru","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jibin","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jianguang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Z\u00fcrcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabrice","family":"Gallou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2017.09.008_h0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.4414\/smw.2001.09702","article-title":"Cyclosporin A, a peptide metabolite from Trichoderma polysporum (Link ex Pers.) Rifai, with immunosuppressive activity","volume":"131","author":"Heusler","year":"2001","journal-title":"Swiss Med Wkly"},{"key":"10.1016\/j.bmc.2017.09.008_h0010","first-page":"1075","article-title":"Cyclosporin with immunosuppressive activity","volume":"59","author":"Ruegger","year":"1976","journal-title":"Helv Chim Acta"},{"key":"10.1016\/j.bmc.2017.09.008_h0015","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1016\/S0140-6736(78)91970-0","article-title":"Cyclosporin A in patients receiving renal allografts from cadaver donors","volume":"312","author":"Calne","year":"1978","journal-title":"Lancet"},{"key":"10.1016\/j.bmc.2017.09.008_h0020","doi-asserted-by":"crossref","first-page":"953","DOI":"10.2165\/00003495-199345060-00007","article-title":"Cyclosporin: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in immunoregulatory disorders","volume":"45","author":"Faulds","year":"1993","journal-title":"Drugs"},{"key":"10.1016\/j.bmc.2017.09.008_h0025","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0031-6997(25)00027-4","article-title":"Pharmacology of cyclosporine","volume":"41","author":"Borel","year":"1989","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.bmc.2017.09.008_h0030","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1126\/science.3885394","article-title":"Cyclosporin A binding to calmodulin: a possible site of action on T lymphocytes","volume":"228","author":"Columbani","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.bmc.2017.09.008_h0035","first-page":"365","article-title":"Immunophilin sensitive protein phosphatase action in cell signaling pathways","volume":"70","author":"Schreiber","year":"1992","journal-title":"Minirev Cell"},{"key":"10.1016\/j.bmc.2017.09.008_h0040","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1016\/0167-5699(92)90111-J","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"13","author":"Schreiber","year":"1992","journal-title":"Immunol Today"},{"key":"10.1016\/j.bmc.2017.09.008_h0045","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0162-3109(00)00192-2","article-title":"Mechanisms of action of cyclosporine","volume":"47","author":"Matsuda","year":"2000","journal-title":"Immunopharmacology"},{"key":"10.1016\/j.bmc.2017.09.008_b0020","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1021\/jm500223x","article-title":"From chemical tools to clinical medicines: non-immunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds","volume":"57","author":"Sweeney","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.09.008_h0055","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.3390\/v5071684","article-title":"Cyclophilins as modulators of viral replication","volume":"5","author":"Frausto","year":"2013","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2017.09.008_h0060","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1111\/j.1365-2249.2010.04115.x","article-title":"Cyclophilin-CD147 interactions: a new target for anti-inflammatory therapeutics","volume":"160","author":"Yurchenko","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.bmc.2017.09.008_h0065","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/SHK.0b013e31824bc9ab","article-title":"The role of cyclosporine in the treatment of myocardial reperfusion injury","volume":"37","author":"Gill","year":"2012","journal-title":"Shock"},{"key":"10.1016\/j.bmc.2017.09.008_h0070","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/1756-9966-29-97","article-title":"Current implications of cyclophilins in human cancers","volume":"29","author":"Lee","year":"2010","journal-title":"J Exp Clin Cancer Res"},{"key":"10.1016\/j.bmc.2017.09.008_b0030","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.3390\/v4112558","article-title":"Cyclophilin inhibitors: an emerging class of therapeutics for the treatment of chronic hepatitis C infection","volume":"4","author":"Hopkins","year":"2012","journal-title":"Viruses"},{"key":"10.1016\/j.bmc.2017.09.008_b0035","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1517\/13543784.2012.658641","article-title":"Update on alisporivir in treatment of viral hepatitis C","volume":"21","author":"Flisiak","year":"2012","journal-title":"Expert Opin Invest Drugs"},{"key":"10.1016\/j.bmc.2017.09.008_b0040","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1128\/AAC.00919-12","article-title":"Multiple mutations in hepatitis C virus NS5A domain II are required to confer a significant level of resistance to alisporivir","volume":"56","author":"Garcia-Rivera","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.bmc.2017.09.008_h0090","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1080\/03602530802341133","article-title":"Drug-induced hyperbilirubinemia and the clinical influencing factors","volume":"40","author":"Ah","year":"2008","journal-title":"Drug Metab Rev"},{"key":"10.1016\/j.bmc.2017.09.008_h0095","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/nrd3028","article-title":"Membrane transporters in drug development","volume":"9","author":"Giacomini","year":"2010","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.bmc.2017.09.008_b0050","first-page":"2121","article-title":"Semi-synthesis of cyclosporins","volume":"2015","author":"Peel","year":"1850","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.bmc.2017.09.008_h0105","doi-asserted-by":"crossref","first-page":"8503","DOI":"10.1021\/jm500862r","article-title":"Potent nonimmunosuppressive cyclophilin inhibitors with improved pharmaceutical properties and decreased transporter inhibition","volume":"57","author":"Fu","year":"2014","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.09.008_h0110","unstructured":"Fu J, Karur S, Li X, et al. Cyclic peptides and use as medicines. WO 2014049540."},{"key":"10.1016\/j.bmc.2017.09.008_b0060","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1021\/jm00048a002","article-title":"Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain","volume":"37","author":"Papageorgiou","year":"1994","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.09.008_b0065","doi-asserted-by":"crossref","first-page":"4598","DOI":"10.1021\/jm0109863","article-title":"Cyclosporins: structure\u2212activity relationships for the inhibition of the human MDR1 P-glycoprotein ABC transporter","volume":"45","author":"Loor","year":"2002","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmc.2017.09.008_b0070","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1021\/op5003038","article-title":"Development of a practical process for the opening of macrocyclic cyclosporin a and amino acid deletion","volume":"18","author":"Riss","year":"2014","journal-title":"Org Proc Res Dev"},{"key":"10.1016\/j.bmc.2017.09.008_b0075","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1021\/jo100233u","article-title":"An organocatalyzed enantioselective synthesis of (2S,3R,4S)-4-hydroxyisoleucine and its stereoisomers","volume":"75","author":"Kumaraswamy","year":"2010","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2017.09.008_b0080","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1002\/anie.199520121","article-title":"Synthesis of chiral \u03b3,\u03b4-unsaturated amino acids by asymmetric ester enolate claisen rearrangement","volume":"34","author":"Kazmaier","year":"1995","journal-title":"Angew Chem Int Ed Engl"},{"key":"10.1016\/j.bmc.2017.09.008_h0140","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1111\/reel.12083","article-title":"Regulating chemical substances under REACH: the choice between authorization and restriction and the case of dipolar aprotic solvents","volume":"23","author":"Bergkamp","year":"2014","journal-title":"Rev Euro Comp Int Env Law"},{"key":"10.1016\/j.bmc.2017.09.008_h0145","unstructured":"See: http:\/\/echa.europa.eu\/substance-information\/-\/substanceinfo\/100.000.617."},{"key":"10.1016\/j.bmc.2017.09.008_h0150","first-page":"509","article-title":"Contemporary strategies for peptide macrocyclization","volume":"3","author":"Christopher","year":"2011","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2017.09.008_h0155","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1021\/op0580015","article-title":"First scale-up to production scale of a ring closing metathesis reaction forming a 15-membered macrocycle as a precursor of an active pharmaceutical ingredient","volume":"9","author":"Nicola","year":"2005","journal-title":"Org Proc Res Dev"},{"key":"10.1016\/j.bmc.2017.09.008_h0160","doi-asserted-by":"crossref","first-page":"7133","DOI":"10.1021\/jo060285j","article-title":"Efficient large-scale synthesis of BILN 2061, a potent HCV protease inhibitor, by a convergent approach based on ring-closing metathesis","volume":"71","author":"Yee","year":"2006","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2017.09.008_h0165","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1021\/ol800183x","article-title":"RCM macrocyclization made practical: an efficient synthesis of HCV protease inhibitor BILN 2061","volume":"10","author":"Shu","year":"2008","journal-title":"Org Lett"},{"key":"10.1016\/j.bmc.2017.09.008_h0170","doi-asserted-by":"crossref","first-page":"7576","DOI":"10.1021\/acs.joc.7b01308","article-title":"Phase separation macrocyclization in a complex pharmaceutical setting: application toward the synthesis of vaniprevir","volume":"82","author":"Godin","year":"2017","journal-title":"J Org Chem"},{"key":"10.1016\/j.bmc.2017.09.008_b0095","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1021\/op800225f","article-title":"Second-generation process for the HCV protease inhibitor BILN 2061: a greener approach to Ru-catalyzed ring-closing metathesis","volume":"13","author":"Farina","year":"2009","journal-title":"Org Proc Res Dev"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617312233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089617312233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:53:41Z","timestamp":1760835221000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089617312233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["S0968089617312233"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2017.09.008","relation":{},"ISSN":["0968-0896"],"issn-type":[{"type":"print","value":"0968-0896"}],"subject":[],"published":{"date-parts":[[2018,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Development of a cyclosporin A derivative with excellent anti-hepatitis C virus potency","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2017.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}